Xiaofang Ying

880 total citations
22 papers, 682 citations indexed

About

Xiaofang Ying is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaofang Ying has authored 22 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaofang Ying's work include MicroRNA in disease regulation (3 papers), Virus-based gene therapy research (2 papers) and Cancer Research and Treatments (2 papers). Xiaofang Ying is often cited by papers focused on MicroRNA in disease regulation (3 papers), Virus-based gene therapy research (2 papers) and Cancer Research and Treatments (2 papers). Xiaofang Ying collaborates with scholars based in China and United States. Xiaofang Ying's co-authors include Wenlin Huang, Jiangxue Wu, Xiangqi Meng, Ranyi Liu, Changchuan Pan, Zhizhong Pan, Hongyan Yu, Yi Zhou, Yufang Zuo and Hui Wang and has published in prestigious journals such as Gastroenterology, PLoS ONE and Scientific Reports.

In The Last Decade

Xiaofang Ying

18 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaofang Ying China 10 397 238 190 87 85 22 682
Sun Mi Hong South Korea 13 391 1.0× 139 0.6× 115 0.6× 70 0.8× 44 0.5× 21 619
Ruorong Yan China 8 586 1.5× 165 0.7× 149 0.8× 53 0.6× 180 2.1× 10 786
Jamie M. Dempsey United States 3 471 1.2× 256 1.1× 70 0.4× 34 0.4× 131 1.5× 3 707
Tania Valencia United States 8 380 1.0× 229 1.0× 142 0.7× 69 0.8× 12 0.1× 10 574
Lydia M.M. Smits Netherlands 9 573 1.4× 94 0.4× 79 0.4× 16 0.2× 44 0.5× 10 680
Mingzeng Sun United States 10 312 0.8× 98 0.4× 109 0.6× 24 0.3× 45 0.5× 15 585
Niels van den Broek United Kingdom 6 597 1.5× 166 0.7× 171 0.9× 30 0.3× 25 0.3× 7 696
Ray-Whay Chiu Yen United States 6 701 1.8× 100 0.4× 174 0.9× 39 0.4× 297 3.5× 7 995
Meixia Bi United States 7 636 1.6× 234 1.0× 75 0.4× 45 0.5× 35 0.4× 15 1.1k
Alan J. Diehl United States 4 397 1.0× 198 0.8× 80 0.4× 50 0.6× 17 0.2× 7 675

Countries citing papers authored by Xiaofang Ying

Since Specialization
Citations

This map shows the geographic impact of Xiaofang Ying's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofang Ying with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofang Ying more than expected).

Fields of papers citing papers by Xiaofang Ying

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofang Ying. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofang Ying. The network helps show where Xiaofang Ying may publish in the future.

Co-authorship network of co-authors of Xiaofang Ying

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofang Ying. A scholar is included among the top collaborators of Xiaofang Ying based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofang Ying. Xiaofang Ying is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Lu, Xiaofang Ying, Guoliang Pi, et al.. (2025). Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting. BMC Cancer. 25(1). 16–16. 1 indexed citations
2.
Zhang, Boyu, Jingxuan Peng, Ning Ma, et al.. (2025). EGF-Upregulated lncRNA ESSENCE Promotes Colorectal Cancer Growth through Stabilizing CAD and Ferroptosis Defense. Research. 8. 649–649.
3.
Ying, Xiaofang, et al.. (2025). Both Arthroscopically Assisted Suture Button and Hook Plate Are Effective in Treating Acute High‐grade Acromioclavicular Joint Dislocation: A Systematic Review. Arthroscopy The Journal of Arthroscopic and Related Surgery. 41(9). 3733–3733.
5.
Chen, Xiaofei, et al.. (2024). Vascular endothelial function and its response to moderate-intensity aerobic exercise in trained and untrained healthy young men. Scientific Reports. 14(1). 20450–20450. 1 indexed citations
6.
Ying, Liwei, et al.. (2023). Epidermoid cyst beneath the scar after total knee arthroplasty: a case report. Journal of Surgical Case Reports. 2023(4). rjad208–rjad208.
8.
Liu, Chao, et al.. (2022). Association of continuous glucose monitoring-derived time in range with major amputation risk in diabetic foot osteomyelitis patients undergoing amputation. Therapeutic Advances in Endocrinology and Metabolism. 13. 2435468617–2435468617. 9 indexed citations
9.
Ying, Xiaofang, Jianping Bi, Yi Ding, et al.. (2021). Management and Outcomes of Patients With Radiotherapy Interruption During the COVID-19 Pandemic. Frontiers in Oncology. 11. 754838–754838. 2 indexed citations
11.
Ying, Xiaofang, Ming‐Wei Wang, Vivek Verma, et al.. (2017). Metastatic spread of solid subtype lung adenocarcinoma to the small intestine with anemia and melena. Medicine. 96(34). e7768–e7768. 6 indexed citations
12.
Tan, Xin, Shuai Chen, Jiangxue Wu, et al.. (2017). PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407. Cell Death and Disease. 8(3). e2686–e2686. 74 indexed citations
13.
Yu, Hongyan, Wen Ye, Jiangxue Wu, et al.. (2014). Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer. Clinical Cancer Research. 20(13). 3434–3445. 115 indexed citations
14.
Ye, Wen, Ranyi Liu, Changchuan Pan, et al.. (2014). Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma. Molecular Therapy. 22(6). 1221–1229. 36 indexed citations
15.
Meng, Xiangqi, Jiangxue Wu, Changchuan Pan, et al.. (2013). Genetic and Epigenetic Down-regulation of MicroRNA-212 Promotes Colorectal Tumor Metastasis via Dysregulation of MnSOD. Gastroenterology. 145(2). 426–436.e6. 103 indexed citations
16.
Ying, Xiaofang, Jiangxue Wu, Xiangqi Meng, et al.. (2013). AC133 expression associated with poor prognosis in stage II colorectal cancer. Medical Oncology. 30(1). 356–356. 13 indexed citations
17.
Yu, Hongyan, Xiangqi Meng, Jiangxue Wu, et al.. (2013). Cryptochrome 1 Overexpression Correlates with Tumor Progression and Poor Prognosis in Patients with Colorectal Cancer. PLoS ONE. 8(4). e61679–e61679. 63 indexed citations
18.
Wang, Hui, Jiangxue Wu, Xiangqi Meng, et al.. (2011). MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 32(7). 1033–1042. 140 indexed citations
19.
Zuo, Yufang, Jiangxue Wu, Zumin Xu, et al.. (2011). Minicircle-oriP-IFNγ: A Novel Targeted Gene Therapeutic System for EBV Positive Human Nasopharyngeal Carcinoma. PLoS ONE. 6(5). e19407–e19407. 20 indexed citations
20.
Xiao, Gang, et al.. (2009). Vision-Based Perceptive Framework for Fish Motion. 16. 1–4. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026